About BioVeda China Fund
BioVeda China Fund is a company based in Huangpu (China). VC firm funding companies in China and the US. It operates on a B2B model.
Company details
BioVeda China Fund functions as a venture capital entity with a focus on healthcare sectors, including HealthTech, medical devices, diagnostics, and healthcare services. Investments are targeted at companies operating in China and the US. Portfolio holdings encompass firms such as MicuRx Pharmaceuticals, Clarus Therapeutics, Quark Pharmaceuticals, and Cathay Biotech. Assets under management are valued at 400 million, with operations based in Huangpu, China.
- Headquarters Huangpu, China
- Website bvcf.com
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Bioveda China Fund
Complete news archive for BioVeda China Fund
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BioVeda China Fund
BioVeda China Fund is headquartered in Huangpu, China. It is registered at Huangpu, Shanghai, China.
BioVeda China Fund functions as a venture capital entity with a focus on healthcare sectors, including HealthTech, medical devices, diagnostics, and healthcare services. Investments are targeted at companies operating in China and the US. Portfolio holdings encompass firms such as MicuRx Pharmaceuticals, Clarus Therapeutics, Quark Pharmaceuticals, and Cathay Biotech. Assets under management are valued at 400 million, with operations based in Huangpu, China.